Evidence map›Paper›PMID 40593647›Full record

ArticleNature communications2025

Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies.

Isabelle Damei, Aziza Caidi, Edouard Auclin, Julien Adam, Sébastien Mella, Milena Hasan, Eric Tartour, Caroline Robert, Stéphanie Corgnac, Fathia Mami-Chouaib

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. FOXP1 Knockdown Reprograms Th9 CAR-T Cells to Overcome Antigen Escape.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Innovative immunotherapeutic strategies for thyroid cancer: challenges and opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. CD8Frontiers in immunology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Isabelle DameiINSERM UMR 1186, Integrative Tumour Immunology and Immunotherapy, Gustave Roussy, Faculte de Médecine-Universite Paris-Sud, Université Paris-Saclay, Villejuif, France.ORCID http://orcid.org/0000-0001-6569-6027
Aziza CaidiINSERM UMR 1186, Integrative Tumour Immunology and Immunotherapy, Gustave Roussy, Faculte de Médecine-Universite Paris-Sud, Université Paris-Saclay, Villejuif, France.
Edouard AuclinDepartment of Medicine, Institut Bergonié, Bordeaux, France.
Julien AdamINSERM UMR 1186, Integrative Tumour Immunology and Immunotherapy, Gustave Roussy, Faculte de Médecine-Universite Paris-Sud, Université Paris-Saclay, Villejuif, France.
Sébastien MellaSingle Cell Biomarkers UTechS, Institut Pasteur, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0002-8679-5718
Milena HasanSingle Cell Biomarkers UTechS, Institut Pasteur, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0002-0879-7099
Eric TartourINSERM U970, Paris Cardiovascular Research Centre, Université Paris-Descartes, Sorbonne Paris Cité, Equipe Labellisée Ligue Contre le Cancer, Hôpital Européen Georges Pompidou, Service d'Immunologie Biologique, Paris, France.ORCID http://orcid.org/0000-0002-7323-468X
Caroline RobertDermatology Unit, Department of Oncology, Institut Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0002-9493-0238
Stéphanie CorgnacINSERM UMR 1186, Integrative Tumour Immunology and Immunotherapy, Gustave Roussy, Faculte de Médecine-Universite Paris-Sud, Université Paris-Saclay, Villejuif, France.ORCID http://orcid.org/0000-0002-3014-9178
Fathia Mami-ChouaibINSERM UMR 1186, Integrative Tumour Immunology and Immunotherapy, Gustave Roussy, Faculte de Médecine-Universite Paris-Sud, Université Paris-Saclay, Villejuif, France. fathia.mami-chouaib@gustaveroussy.fr.ORCID http://orcid.org/0000-0001-9685-6011

Funding

Bristol-Myers Squibb Foundation (BMSF) CA209-942
6 · The paper itself

Abstract

The involvement of tumour-resident memory T (T

Indexed as

CTLA-4 AntigenImmune Checkpoint InhibitorsImmunologic MemoryImmunotherapyMemory T CellsProgrammed Cell Death 1 ReceptorT-Lymphocyte SubsetsAnimalsAntigens, CDCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansIntegrin alpha ChainsLymphocytes, Tumor-Infiltratingalpha E integrinsAntigens, CDCTLA-4 AntigenImmune Checkpoint InhibitorsIntegrin alpha ChainsProgrammed Cell Death 1 Receptor

Identifiers

PMID40593647
PMCPMC12216323

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.